uniQure N.V. (0EE0.L)
USD 16.7
(1.06%)
USD 16.7
(1.06%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -308.47 Million USD | -143.3% |
| 2022 | -126.78 Million USD | -138.47% |
| 2021 | 329.58 Million USD | 363.62% |
| 2020 | -125.02 Million USD | 2.33% |
| 2019 | -128.01 Million USD | -53.67% |
| 2018 | -83.3 Million USD | -3.63% |
| 2017 | -80.38 Million USD | -9.56% |
| 2016 | -73.37 Million USD | 6.11% |
| 2015 | -78.14 Million USD | -73.51% |
| 2014 | -45.04 Million USD | -21.62% |
| 2013 | -37.03 Million USD | -90.29% |
| 2012 | -19.46 Million USD | 13.2% |
| 2011 | -22.42 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -44.37 Million USD | 21.17% |
| 2024 Q1 | -65.61 Million USD | 10.37% |
| 2024 Q2 | -56.29 Million USD | 14.2% |
| 2023 Q3 | -89.57 Million USD | -30.81% |
| 2023 Q4 | -73.2 Million USD | 18.27% |
| 2023 FY | -308.47 Million USD | -143.3% |
| 2023 Q1 | -77.22 Million USD | -1234.52% |
| 2023 Q2 | -68.47 Million USD | 11.33% |
| 2022 FY | -126.78 Million USD | -138.47% |
| 2022 Q2 | -39.06 Million USD | 16.32% |
| 2022 Q1 | -46.67 Million USD | -668.69% |
| 2022 Q4 | 6.8 Million USD | 114.22% |
| 2022 Q3 | -47.85 Million USD | -22.52% |
| 2021 Q2 | 399.46 Million USD | 1061.28% |
| 2021 Q4 | 8.2 Million USD | 122.47% |
| 2021 Q3 | -36.53 Million USD | -109.14% |
| 2021 Q1 | -41.55 Million USD | -5845.06% |
| 2021 FY | 329.58 Million USD | 363.62% |
| 2020 Q1 | -27.99 Million USD | 32.41% |
| 2020 Q3 | -53.77 Million USD | -26.38% |
| 2020 Q4 | -699 Thousand USD | 98.7% |
| 2020 FY | -125.02 Million USD | 2.33% |
| 2020 Q2 | -42.55 Million USD | -51.97% |
| 2019 Q3 | -23.6 Million USD | 24.83% |
| 2019 Q2 | -31.39 Million USD | -13.06% |
| 2019 Q1 | -27.77 Million USD | -26.88% |
| 2019 FY | -128.01 Million USD | -53.67% |
| 2019 Q4 | -41.42 Million USD | -75.5% |
| 2018 Q3 | -22.03 Million USD | -7.01% |
| 2018 Q1 | -18.78 Million USD | 31.61% |
| 2018 Q4 | -21.88 Million USD | 0.67% |
| 2018 FY | -83.3 Million USD | -3.63% |
| 2018 Q2 | -20.59 Million USD | -9.6% |
| 2017 Q4 | -27.47 Million USD | -168.17% |
| 2017 Q3 | -10.24 Million USD | 51.83% |
| 2017 Q2 | -21.26 Million USD | -4.92% |
| 2017 FY | -80.38 Million USD | -9.56% |
| 2017 Q1 | -20.27 Million USD | -50.9% |
| 2016 Q1 | -23.31 Million USD | -71.5% |
| 2016 FY | -73.37 Million USD | 6.11% |
| 2016 Q3 | -15.16 Million USD | 29.46% |
| 2016 Q2 | -21.5 Million USD | 7.79% |
| 2016 Q4 | -13.43 Million USD | 11.44% |
| 2015 FY | -78.14 Million USD | -73.51% |
| 2015 Q4 | -13.59 Million USD | 53.24% |
| 2015 Q1 | -13.68 Million USD | -12.15% |
| 2015 Q3 | -29.07 Million USD | -37.27% |
| 2015 Q2 | -21.18 Million USD | -54.78% |
| 2014 Q2 | -12.26 Million USD | -13.91% |
| 2014 Q3 | -11.49 Million USD | 6.28% |
| 2014 Q4 | -12.2 Million USD | -6.16% |
| 2014 FY | -45.04 Million USD | -21.62% |
| 2014 Q1 | -10.76 Million USD | -13.71% |
| 2013 Q1 | -6.63 Million USD | -9.13% |
| 2013 Q2 | -10.12 Million USD | -52.69% |
| 2013 Q3 | -9.49 Million USD | 6.22% |
| 2013 Q4 | -9.46 Million USD | 0.29% |
| 2013 FY | -37.03 Million USD | -90.29% |
| 2012 Q3 | -4.6 Million USD | 0.0% |
| 2012 FY | -19.46 Million USD | 13.2% |
| 2012 Q4 | -6.07 Million USD | -31.85% |
| 2011 FY | -22.42 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -101.331% |
| Dynavax Technologies Corporation | -6.38 Million USD | -4728.267% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 23540.578% |
| Perrigo Company plc | -12.7 Million USD | -2328.961% |
| Illumina, Inc. | -1.16 Billion USD | 73.43% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 105.146% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 30.529% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 96.428% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 122.716% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -179.017% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 107.802% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -673.904% |
| Waters Corporation | 642.23 Million USD | 148.032% |
| Biogen Inc. | 1.16 Billion USD | 126.568% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -19.643% |
| Evolus, Inc. | -61.68 Million USD | -400.086% |
| Adicet Bio, Inc. | -142.65 Million USD | -116.236% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -160.29% |
| bluebird bio, Inc. | -211.91 Million USD | -45.568% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -47.422% |
| FibroGen, Inc. | -284.23 Million USD | -8.53% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 124.877% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -591.603% |
| Homology Medicines, Inc. | -53.74 Million USD | -473.987% |
| Geron Corporation | -184.12 Million USD | -67.535% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 29.93% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -103.503% |
| Myriad Genetics, Inc. | -112 Million USD | -175.427% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -259.134% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 35.893% |
| Zoetis Inc. | 2.34 Billion USD | 113.16% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -469.274% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 139.108% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 284.007% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 108.522% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -631.008% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 15.782% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -11.716% |
| Verastem, Inc. | -87.36 Million USD | -253.083% |
| Nektar Therapeutics | -276.05 Million USD | -11.745% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -28.942% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -248.638% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 42.446% |
| OPKO Health, Inc. | -188.86 Million USD | -63.334% |
| Exelixis, Inc. | 207.76 Million USD | 248.474% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 223.539% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 390.633% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -549.359% |
| Imunon, Inc. | -19.51 Million USD | -1480.724% |
| Blueprint Medicines Corporation | -506.98 Million USD | 39.154% |
| Insmed Incorporated | -749.56 Million USD | 58.846% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 209.547% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 12.386% |
| TG Therapeutics, Inc. | 12.67 Million USD | 2534.328% |
| Incyte Corporation | 597.59 Million USD | 151.62% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 59.437% |